Matthew Hudes is the Founder and CEO of bdlBiologx, a company devoted to helping the products of innovative companies reach patients more quickly. bdlBiologx provides 1) On-demand services to stimulate company growth 2) leading-edge Business Development and Licensing (BDL) processes and systems, and 3) capability-building to support the growth of a BDL function within a company.
a single-point of contact for a deal
a team of experienced professionals
a network of industry, science, financial, and law resources
an objective sounding-board for portfolio decisions
a source of BDL best practices
a coach to a company building its BDL capabilities
For the prior 11 years, Matthew was the BioPharma practice leader for Deloitte. He has a long history of serving the BioPharma industry and has developed numerous biologics manufacturing strategies and operating models. He speaks frequently about such topics as manufacturing and quality, regulatory compliance, supply chain, fostering innovation, personalized medicine, the use of technology for innovating clinical research, and finance transformation,
Matthew was the executive sponsor of Deloitte’s unique innovation collaboration with the University of California, and served as the Lead Client Service Principal for Amgen, Patheon, and the California Institute for Quantitative Biosciences (QB3). He served as a member of the Board of Directors of BIOCOM and of the Bay Area BioEconomy Initiative, and as a faculty member and executive sponsor of the UC Berkeley BioExec Institute.
Previously, he was the Chairman and CEO of Accélère, a software company that developed a system to find patients (and investigators) for clinical trials and to improve researchers’ access to information typically “trapped” in laboratory and medical systems, and prior to that was a partner and leader of Ernst & Young’s Life Sciences practice.